1 / 8

Analyze future: Acute Sensorineural Hearing Loss - Pipeline

Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014’, provides an overview of the Acute Sensorineural Hearing Loss’s therapeutic pipeline. To Get More Info. Visit: http://www.analyzefuture.com/acute-sensorineural-hearing-loss-pipeline-review-h2-2014-market This report provides comprehensive information on the therapeutic development for Acute Sensorineural Hearing Loss, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Sensorineural Hearing Loss and special features on late-stage and discontinued projects.

melinda_veteel
Download Presentation

Analyze future: Acute Sensorineural Hearing Loss - Pipeline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014 No. Pages : 47 Published on : Dec-2014

  2. Report Description Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014’, provides an overview of the Acute Sensorineural Hearing Loss’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Sensorineural Hearing Loss, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Sensorineural Hearing Loss and special features on late-stage and discontinued projects. To Get More Info. Visit : http://www.analyzefuture.com/acute-sensorineural-hearing-loss-pipeline-review-h2-2014-market Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  3. Report Description Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. To Enquire About Report @ http://www.analyzefuture.com/acute-sensorineural-hearing-loss-pipeline-review-h2-2014-market/report-enquiry

  4. Table of Content Table Of ContentsTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Acute Sensorineural Hearing Loss Overview 6Therapeutics Development 7Pipeline Products for Acute Sensorineural Hearing Loss - Overview 7Pipeline Products for Acute Sensorineural Hearing Loss - Comparative Analysis 8Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies 9Acute Sensorineural Hearing Loss - Pipeline Products Glance 10Late Stage Products 10Clinical Stage Products 11Early Stage Products 12Acute Sensorineural Hearing Loss - Products under Development by Companies 13Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development 14

  5. Table of Content NordmarkArzneimittel GmbH & Co. KG 14Orbis Biosciences, Inc. 15Otologic Pharmaceutics, Inc. 16Pfizer Inc. 17Sound Pharmaceuticals, Inc. 18Xigen SA 19Acute Sensorineural Hearing Loss - Therapeutics Assessment 20Assessment by Monotherapy Products 20Assessment by Combination Products 21Assessment by Target 22Assessment by Mechanism of Action 24Assessment by Route of Administration 26Assessment by Molecule Type 28Drug Profiles 30(acetylcysteine + disufenton sodium) - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30ancrod - Drug Profile 31

  6. Table of Content Product Description 31Mechanism of Action 31R&D Progress 31betamethasone valerate - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33PF-04958242 - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35SPI-1005 - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36

  7. Table of Content Stem Cell Therapy for Sensorineural Hearing Loss - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38XG-102 - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39Acute Sensorineural Hearing Loss - Recent Pipeline Updates 41Acute Sensorineural Hearing Loss - Product Development Milestones 43Featured News & Press Releases 43Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders 43Feb 18, 2014: Sound Pharmaceuticals submits positive Phase 2 clinical trial data on SPI-1005 for the prevention and treatment of sensorineural hearing loss 43Dec 05, 2012: University Of Florida Begins Phase-II Trial With Sound Pharma's SPI-1005 To Prevent Hearing Loss 44 To Get Complete TOC Visit at: http://www.analyzefuture.com/acute-sensorineural-hearing-loss-pipeline-review-h2-2014-market/table-of-contents

  8. FOR MORE DETAILS Visit us at : http://www.analyzefuture.com/ Stay With Us: 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States. TELEPHONE: +1 (855) 711-1555 EMAIL: sales@analyzefuture.com

More Related